Global and United States Rabies Immune Globulin (Human) Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Rabies Immune Globulin (Human) Market Report & Forecast 2024-2034
Market Analysis and InsightsGlobal and United States Rabies Immune Globulin (Human) Market
This report focuses on global and United States Rabies Immune Globulin (Human) market, also covers the segmentation data of other regions in regional level and county level.
The global Rabies Immune Globulin (Human) revenue was US$ 1500 million in 2022 and is forecast to a readjusted size of US$ 1973.9 million by 2034 with a CAGR of 4.0% during the forecast period (2024-2034).
The market for Rabies Immune Globulin (Human) is primarily driven by the incidence of rabies in different regions of the world. According to the World Health Organization, rabies is present in more than 150 countries, with an estimated 59,000 human deaths annually. The majority of these deaths occur in Asia and Africa, where access to post-exposure prophylaxis may be limited.
In addition, the market for Rabies Immune Globulin (Human) is also influenced by government policies and regulations related to rabies prevention and control. Many countries have established national vaccination programs and guidelines for post-exposure prophylaxis, which may include the use of Rabies Immune Globulin (Human).
Overall, the market for Rabies Immune Globulin (Human) is expected to continue to grow as awareness of rabies and the importance of post-exposure prophylaxis increases, particularly in regions with high incidence of the disease.
Global Rabies Immune Globulin (Human) Scope and Market Size
Rabies Immune Globulin (Human) market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Rabies Immune Globulin (Human) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2024-2034.
For United States market, this report focuses on the Rabies Immune Globulin (Human) market size by players, by Type and by Application, for the period 2024-2034. The key players include the global and local players, which play important roles in United States.
CSL Behring
Grifols
Sanofi
Kamada
Bharat Serum
Bio Products Laboratory
Shanghai RAAS
Weiguang Bio
Shuanglin Bio
CBPO
CNBG
Sichuan Yuanda Shuyang
Kedrion Biopharma
Congruent Pharmachem
hualanbio
Segment by Type
HyperRAB S/D
KEDRAB
Clinic
Hospital
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Rabies Immune Globulin (Human) definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Rabies Immune Globulin (Human) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Rabies Immune Globulin (Human) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rabies Immune Globulin (Human) sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
This report focuses on global and United States Rabies Immune Globulin (Human) market, also covers the segmentation data of other regions in regional level and county level.
The global Rabies Immune Globulin (Human) revenue was US$ 1500 million in 2022 and is forecast to a readjusted size of US$ 1973.9 million by 2034 with a CAGR of 4.0% during the forecast period (2024-2034).
The market for Rabies Immune Globulin (Human) is primarily driven by the incidence of rabies in different regions of the world. According to the World Health Organization, rabies is present in more than 150 countries, with an estimated 59,000 human deaths annually. The majority of these deaths occur in Asia and Africa, where access to post-exposure prophylaxis may be limited.
In addition, the market for Rabies Immune Globulin (Human) is also influenced by government policies and regulations related to rabies prevention and control. Many countries have established national vaccination programs and guidelines for post-exposure prophylaxis, which may include the use of Rabies Immune Globulin (Human).
Overall, the market for Rabies Immune Globulin (Human) is expected to continue to grow as awareness of rabies and the importance of post-exposure prophylaxis increases, particularly in regions with high incidence of the disease.
Global Rabies Immune Globulin (Human) Scope and Market Size
Rabies Immune Globulin (Human) market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Rabies Immune Globulin (Human) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2024-2034.
For United States market, this report focuses on the Rabies Immune Globulin (Human) market size by players, by Type and by Application, for the period 2024-2034. The key players include the global and local players, which play important roles in United States.
By Company
CSL Behring
Grifols
Sanofi
Kamada
Bharat Serum
Bio Products Laboratory
Shanghai RAAS
Weiguang Bio
Shuanglin Bio
CBPO
CNBG
Sichuan Yuanda Shuyang
Kedrion Biopharma
Congruent Pharmachem
hualanbio
Segment by Type
HyperRAB S/D
KEDRAB
Segment by Application
Clinic
Hospital
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Rabies Immune Globulin (Human) definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Rabies Immune Globulin (Human) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Rabies Immune Globulin (Human) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rabies Immune Globulin (Human) sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices